首页> 外文OA文献 >Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis
【2h】

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis

机译:中风关联脑血管疾病临床管理指南:执行摘要及2019年脑静脉血栓形成临床管理的更新

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim Cerebral venous sinus thrombosis (CVST) is a less common cerebrovascular disease that predominantly affects young patients. The incidence of CVST is 2–5/10 000 000/year, accounting for 0.5%–1% of all stroke. To reduce mortality and morbidity associated with CVST, Chinese Stroke Association commissioned the authors to write the current guideline on the management of CVST.Methods PubMed (MEDLINE), CNKI and Wanfang database were searched for studies related to CVST from 1 January 1990 to 31 July 2019. Data were synthesised by evidence tables. Each recommendation was fully discussed by the writing group members and reviewed by Chinese Stroke Association Stroke Fellow Committees. Levels of evidence grading algorithm of Chinese Stroke Association was used to grade each recommendation.Results This guideline mainly focuses on the diagnostic evaluation, therapeutic strategies and secondary prevention of CVST. CT/CTV and MRI/MRV are recommended in the initial imaging evaluation of patients with suspected CVST. Anticoagulation therapy with low-molecular weight heparin should be initiated in patients with CVST immediately. After the acute stage, warfarin is recommended for 3–6 months to prevent the recurrence of CVST and other venous thromboembolic events.Conclusions The guideline summarises the current evidence regarding the management of CVST, and provides references for diagnosis, treatment and secondary prevention of CVST in China.
机译:目的脑静脉窦血栓形成(CVST)是一种不太常见的脑血管疾病,主要影响年轻患者。 CVST的发病率是2-5 / 10 000 000 /年,占0.5%-1所有中风%。为了减少与关联CVST发病率和死亡率,中国卒中协会委托作者来写CVST.Methods考研(MEDLINE)的管理目前的方针,CNKI和万方数据库中搜索了从1 CVST相关性1990年1月至7月31日的研究2019年数据通过证据表合成。每一项建议是由写作组成员充分讨论,并通过中国卒中学会卒中研究员委员会审查。证据分级中国卒中协会的算法水平来分级每个recommendation.Results本指南主要集中在诊断评估,治疗策略和CVST的二级预防。 CT / CTV和MRI / MRV建议患者疑似CVST初始成像评价。与低分子量肝素抗凝治疗的患者应立即开始与CVST。急性期后,华法林,建议3-6个月,以防止CVST和其他静脉血栓栓塞events.Conclusions该指南总结了关于CVST管理的现有证据的复发,并提供诊断,治疗和CVST的二级预防引用在中国。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号